Snowden Capital Advisors LLC Amicus Therapeutics, Inc. Transaction History
Snowden Capital Advisors LLC
- $3.29 Billion
- Q3 2024
A detailed history of Snowden Capital Advisors LLC transactions in Amicus Therapeutics, Inc. stock. As of the latest transaction made, Snowden Capital Advisors LLC holds 34,960 shares of FOLD stock, worth $345,055. This represents 0.01% of its overall portfolio holdings.
Number of Shares
34,960
Previous 50,064
30.17%
Holding current value
$345,055
Previous $496,000
24.8%
% of portfolio
0.01%
Previous 0.01%
Shares
10 transactions
Others Institutions Holding FOLD
# of Institutions
313Shares Held
314MCall Options Held
516KPut Options Held
833K-
Vanguard Group Inc Valley Forge, PA28.8MShares$284 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY28.1MShares$277 Million7.83% of portfolio
-
Black Rock Inc. New York, NY24.4MShares$241 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA24MShares$237 Million0.05% of portfolio
-
Avoro Capital Advisors LLC New York, NY23.2MShares$229 Million3.72% of portfolio
About AMICUS THERAPEUTICS, INC.
- Ticker FOLD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 280,497,984
- Market Cap $2.77B
- Description
- Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...